ARCH Venture Partners
Not publicly disclosed in reviewed sources · company-creation, seed, series-a, growth · US, Europe, Global science networks
ARCH Venture Partners invests at company-creation, seed, series-a, growth across US, Europe, Global science networks. Current capital evidence: More than $3B ARCH Venture Fund XIII. Founder access: No dedicated public founder pitch route was confirmed; target a named investor through a trusted introduction without inferring an email pattern.
Tier 2 · ranked #49bio
Visit / pitchOfficial siteOpen in the live directory
Key facts
| Fund size | More than $3B ARCH Venture Fund XIII |
| Stage | company-creation, seed, series-a, growth |
| Typical first check | Not publicly disclosed in reviewed sources |
| Sectors | bio, therapeutics, health, deep-tech |
| Geography | US, Europe, Global science networks |
| Status | unknown |
Always confirm on the official page before applying — dates and terms change.
Background
Leading biotech firm co-founding companies from breakthrough science. This 2026-08-10 pass verified current capital, team, strategy, portfolio, founder-access and support evidence while keeping private mechanics explicitly unknown.
How the application really works
No dedicated public founder pitch route was confirmed; target a named investor through a trusted introduction without inferring an email pattern.
Tips
- Show direct fit to company-creation / seed / series-a / growth and US / Europe / Global science networks.
- Approach a named investor whose official remit matches the company; do not infer personal contact details.
- Explain fit with the current disclosed vehicle ($3B+).
Watch out for
- Outside the stated stage, sector or geography.
- Using media, LP or corporate-partnership contacts as founder pitch routes.
- Treating unpublished ownership, check or decision-speed data as guaranteed.
Track record
- Official portfolio identifies public companies including Illumina, Alnylam, Denali and Twist, plus numerous acquired companies.
- Illumina — retained Layer 1 portfolio example; do not infer realized return without company-level evidence.
- Moderna co-invest — retained Layer 1 portfolio example; do not infer realized return without company-level evidence.
- Denali — retained Layer 1 portfolio example; do not infer realized return without company-level evidence.
- Sana — retained Layer 1 portfolio example; do not infer realized return without company-level evidence.
No application funnel or investment acceptance rate is published in the reviewed sources.
Investment thesis
Build transformative biotech companies from the earliest science.
How to reach them
- Twitter/X: @ARCHVenture
- No dedicated public founder pitch route was confirmed; target a named investor through a trusted introduction without inferring an email pattern.
Notable portfolio
IlluminaModerna co-investDenaliSana
Frequently asked questions
- What stages does the fund target?
- company-creation, seed, series-a, growth
- Where does it invest?
- US, Europe, Global science networks
- What capital is currently disclosed?
- More than $3B ARCH Venture Fund XIII
- How can founders reach the fund?
- No dedicated public founder pitch route was confirmed; target a named investor through a trusted introduction without inferring an email pattern.
- Does it lead and what ownership does it target?
- No uniform lead or ownership target is published.
- How does the decision process work?
- The complete investment-committee process is not published.
Related venture funds
Sources
- www.archventure.com/arch-venture-partners-announces-new-fund-xiii — Official capital, strategy or current-activity evidence. (checked 2026-08-10)
- www.archventure.com/team — Official team evidence. (checked 2026-08-10)
- www.archventure.com/about — Official founder-support, intake or strategy evidence. (checked 2026-08-10)
- www.archventure.com/portfolio — Official portfolio and track-record evidence. (checked 2026-08-10)